Site search
2893 results for '' found
Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement (NCT02701283)
Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement (NCT02701283)
/
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Subjects and in Subjects with Parkinson’s disease (N
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Subjects and in Subjects with Parkinson’s disease (N
/
A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous tre
A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous tre
/
A Phase 1b/2a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory effi
A Phase 1b/2a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory effi
/
Long-Term Outcomes of Lidocaine Infusions for Post-Operative Pain: the LOLIPOP Trial (NCT05072314)
Long-Term Outcomes of Lidocaine Infusions for Post-Operative Pain: the LOLIPOP Trial (NCT05072314)
/
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM302 in Combination with Toripalimab i
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM302 in Combination with Toripalimab i
/
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as
/
An Observational Multi center Study to Evaluate Real World Treatment Outcomes of Durvalumab based Regimens in Hepatobiliary Cancers [LIVER-R] (NCT06252753)
An Observational Multi center Study to Evaluate Real World Treatment Outcomes of Durvalumab based Regimens in Hepatobiliary Cancers [LIVER-R] (NCT06252753)
/
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept [MK-7962] Administered Using Either a Weight-based or Weight-banded Approach in
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept [MK-7962] Administered Using Either a Weight-based or Weight-banded Approach in
/
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acu
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acu
/